Coronavirus: WHO refuses to back UK’s Covid vaccine dose spacing

World Health Organization refuses to back UK’s move to space Pfizer Covid vaccine doses by 12 weeks because there is no proof it will work

  • British officials told NHS to scrap three-week second dose to save supplies
  • But it has caused anxiety among scientists who say new schedule is untested 
  • WHO official said countries in crisis may need flexibility but didn’t recommend it 

The World Health Organization has refused to give its blessing to Britain’s plan to space the two doses of Pfizer‘s coronavirus vaccine by more than a month.

Officials in the UK have decided to use all available doses of the Pfizer jab, which was the first to be approved, to get a single dose to as many people as possible. In the process they will leave people waiting up to 12 weeks for their second jab. 

Covid-19 cases started to fall around 12 days after people got their first dose in studies but, because everyone got a second shot just 10 days later, scientists don’t know how long immunity from the initial jab would last. 

The WHO yesterday said governments should be giving people their second dose within 21 to 28 days of having the first, to make sure the vaccine works long-term.

But it did not attack Britain’s decision not to do this, admitting the Government had been forced to make a difficult decision because of spiralling infections and deaths in recent weeks.

One of the experts said they ‘totally acknowledge that countries may see needs to be even more flexible in terms of the administration of the second dose’.

It comes after England’s chief medical officer, Professor Chris Whitty, defended the controversial move again last night, saying the benefits of it outweigh the risks. 

He admitted there was a chance it could increase the risk of the virus developing vaccine resistance in the future but that the need to vaccinate people now was overwhelming.

Britain was the first country to start vaccinating members of the public against Covid-19 and has now given jabs to more than 1.3million people, but has had to begin a controversial strategy of stretching the gaps between doses in a bid to protect the elderly from an out-of-control second wave (Pictured: Dr Doreen Brown, 85, gets a vaccine in London)

Britain was the first country to start vaccinating members of the public against Covid-19 and has now given jabs to more than 1.3million people, but has had to begin a controversial strategy of stretching the gaps between doses in a bid to protect the elderly from an out-of-control second wave (Pictured: Dr Doreen Brown, 85, gets a vaccine in London)

Britain was the first country to start vaccinating members of the public against Covid-19 and has now given jabs to more than 1.3million people, but has had to begin a controversial strategy of stretching the gaps between doses in a bid to protect the elderly from an out-of-control second wave (Pictured: Dr Doreen Brown, 85, gets a vaccine in London)

In a meeting to discuss how doses are spaced out yesterday, WHO experts concluded that, with the Pfizer/BioNTech jab, people should get their second dose 21 to 28 days after the first, with an ‘outer limit’ of six weeks.

This is only half as long as the UK plans to leave it, with people being told they could have to wait three months.

Stockpiles are not big enough for the NHS to proceed with its plan of two doses in a month for every patient, so they’re being stretched to go further until more vaccines are delivered in the spring.

The decision was made by the government’s Joint Committee on Vaccination and Immunisation (JCVI) and endorsed by all of the UK’s chief medical officers. 

Dr Alejandro Cravioto, chairman of WHO’s vaccination advisory group, said yesterday: ‘We deliberated and came out with the following recommendation: two doses of this vaccine within 21-28 days.’ 

His colleague Joachim Hombach said the WHO ‘totally acknowledge that countries may see needs to be even more flexible in terms of administration of the second dose. 

‘But it is important to note that there is very little… empirical data from the trials that underpin this type of recommendation.’

Advertisement

Loading

Leave a Reply

Your email address will not be published. Required fields are marked *

Follow by Email
Pinterest
LinkedIn
Share